Cohance Q2 FY26: Revenue down 8% YoY at 555.6 cr; PAT halves

Revenue declinedEBITDA margin compressionResults restatedExceptional itemEmphasis of matterResults View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.3%Reaction day

₹690.45

prior close

₹676.55

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-8.9% vs market

Pharmaceuticals peers, median of 157sector-0.0%-9.3% vs sector

On the reaction day the stock moved 8.9 pts less than Nifty Smallcap 250 and 9.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-4.2

15m

-4.3

30m

-6.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.3-0.4-8.9-0.0-9.3

Next day

-11.0-0.2-10.8-0.4-10.6

-11.6+0.5-12.0-0.3-11.2

-13.9-0.6-13.4-1.0-12.9

-15.5-1.0-14.5-1.3-14.2

-15.7-1.1-14.7-1.5-14.2

-17.2-2.9-14.3-3.2-14.0

15d

-20.4-3.1-17.3-3.4-17.0

-23.1-3.9-19.2-4.0-19.1

-35.1-5.3-29.7-6.6-28.4

-54.8-6.6-48.2-8.5-46.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 revenue fell 8% YoY to 555.6 cr from 603.8 cr on deferred shipments and destocking. Net profit to shareholders halved to 74.1 cr. H1 revenue rose 1.2% to 1,104.9 cr. Gross margin improved to 74.6% from 71.3% but adjusted EBITDA margin slipped to 23.2% from 33.6% in FY25. Company booked 8.10 cr exceptional item for merger restructuring. Prior periods restated for Cohance amalgamation. FY30 target of 1 billion dollars reiterated.

Likely market impact

Soft Q2 with revenue and profit declines, margin compression, and destocking headwinds; management guides stronger H2 and retains FY30 target.